As the global pharmaceutical industry increasingly pivots towards precision therapeutics, liposomal drug delivery systems are emerging as a transformative force in oncology. Litchlab, a pioneering contract development and manufacturing organization (CDMO), is positioning itself at the forefront of this evolution by offering fully integrated R&D and manufacturing solutions for anti-tumor liposomal formulations—from bench to clinic.
Traditional chemotherapeutics often suffer from severe systemic toxicity and limited tumor specificity. Liposomes, by contrast, encapsulate active agents within lipid bilayers, improving bioavailability while reducing off-target toxicity. Litchlab’s platform leverages this principle through advanced engineering of long-circulating, PEGylated liposomes and active-targeting constructs.
Litchlab’s anti-tumor liposome services are optimized for both hydrophobic drugs (e.g., Paclitaxel, SN-38) and hydrophilic agents (e.g., Doxorubicin, Gemcitabine), with proprietary technologies enabling:
Enhanced Passive Targeting via the EPR effect in solid tumors
Surface Engineering with ligands, antibodies, or peptides for active targeting
Controlled Release Kinetics triggered by pH, enzymes, or temperature-sensitive lipids
Stable Long-Circulating Profiles supported by PEGylation and lipid composition tuning
This combination ensures that anti-cancer agents accumulate in tumor tissue more efficiently, increasing efficacy while minimizing systemic side effects.
Litchlab has established a vertically integrated liposome development and manufacturing ecosystem, encompassing:
Through in-house production and international sourcing, Litchlab provides high-purity functional lipids, including:
Ionizable and cationic lipids for nucleic acid combination therapy
Cholesterol and saturated phospholipids with high thermal stability
Custom PEG-lipids for pharmacokinetic modulation
Microfluidic Mixing Systems for nanoprecise control of particle size (typically 80–120 nm)
Reverse Phase Evaporation & Thin-Film Hydration Methods for flexible process adaptation
Drug loading efficiencies >95% for challenging chemotherapeutic payloads
Using DLS, HPLC, Cryo-TEM, and LC-MS platforms, Litchlab ensures control of:
Particle size distribution & polydispersity
Surface charge (Zeta potential)
Drug encapsulation efficiency and leakage profile
In vitro release kinetics and serum stability
To facilitate global market entry, Litchlab supports clients with:
ICH-compliant documentation (Q1–Q8), including analytical validation
IND module authoring and eCTD submission packages
PEG-lipid impurity profiling and extractables/leachables studies
TSE/BSE-free raw material declarations and elemental impurity assessments
The company’s regulatory team has experience supporting both 505(b)(2) submissions and innovative new drug (IND/NDA) filings across the U.S., Europe, and Asia-Pacific markets.
To bridge the gap between lab innovation and clinical delivery, Litchlab offers:
Non-GMP sample production (100+ batches/year for R&D)
GMP manufacturing lines for Phase I/II clinical trials
Lyophilization of liposomes to enhance shelf-life and cold-chain stability
Stability studies under ICH Q1A guidelines (real-time and accelerated)
Litchlab’s facility also enables co-delivery strategies such as liposomal formulations combining anti-PD-1/PD-L1 immunotherapies, or dual-drug encapsulation (e.g., DOX + siRNA) to enhance tumor responsiveness.
The global liposomal drug delivery market is projected to exceed USD $10 billion by 2028, driven largely by oncology applications. Litchlab aims to be a key enabler in this transformation.
“Liposomal technologies are entering a golden era of personalization and combination therapies,” said Dr. Alex Tang, Head of Oncology R&D at Litchlab. “Our goal is to empower biotech innovators and global pharma alike to realize their next-generation oncology programs—faster, smarter, and with regulatory confidence.”
Backed by a global client network and a multidisciplinary team of formulation scientists, chemists, and regulatory specialists, Litchlab is not just building liposomes, but enabling the future of cancer care.
For partnerships, formulation inquiries, or GMP project consultation, please visit:
